Eli Lilly and Company (LLY) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you for holding. We look forward to talking with you soon. Please hold the line and we'll be right back with you. Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q1 2025 earnings conference call. At this time, all participants are on a listen-only mode. Later, we will be conducting a question and answer session and instructions will be given at that time. Should you require assistance during the call, please press star, then zero, and an operator will assist you offline. I would now like to turn the conference over to your host, Mike Zappar, Senior Vice President of Investor Relations. Please go ahead. Good morning. Good morning. Thank you for joining us for Eli Lilly and Company's Q1 2025 earnings call. I'm Mike Spahr, Senior Vice President of Investor Relations. Joining me on today's call are Dave Ricks, Lilly's Chair and CEO, Lucas Montarse, Chief Financial Officer, Dr. Dan Skowronski, Chief Scientific Officer and President of Lilly Immunology, Anne White, President of Lilly Neuroscience, David Hufa, President of Lilly International, Jake Van Narden, President of Lilly Oncology, and Patrick Johnson, President of Cardio Metabolic Health and Lilly USA. We're also joined by Mark Kuhman, Wes Tall, and Wai Wong of the Investor Relations Team. During this conference call, we anticipate making projections and forward-looking statements based on our current expectations. Our actual results could differ materially due to several factors, including those listed on slide four. Additional information concerning factors that could cause actual results to differ materially is contained in our latest form 10-K and subsequent filings with the SEC. The information we provide about our products and pipeline is for the benefit of the investment communi...